The following is a summary of “Anti-proteinuria effect of active vitamin D in patients with type 2 diabetic nephropathy,” published in the December 2022  issue of Primary care by Aref, et al.

Patients with type 2 diabetic nephropathy (DN) frequently experience proteinuria as a consequence. For a study, researchers sought to assess how effectively active vitamin D reduced proteinuria in people with type 2 DN.

About 42 DN patients chosen by convenience sampling were the subjects of a double-blind, randomized clinical trial investigation. Patients were chosen based on inclusion criteria and then randomly assigned to the control or intervention group. The treatment group’s patients got 0.25 mg of active vitamin D daily for 12 weeks. On the first day of the intervention, the patients’ fasting blood sugar (FBS), calcium, phosphorus, creatinine, glomerular filtration rate (GFR), systolic and diastolic blood pressure, and proteinuria were all assessed. At the conclusion of the first, second, and third interventional months, these factors were also assessed. Version 22 of the Statistical Package for Social Sciences program was used for data collection and analysis.

In the study, patients made up 52.5% of men and 47.5% of women on average. The patients’ average age was 55.52± 6.58 years. According to the findings of repeated measures analysis, patients in the intervention group’s proteinuria were considerably reduced by active vitamin D (P = 0.000). For patients in the intervention group, the changes in FBS (P = 0.245), calcium (P = 0.393), phosphorus (P = 0.694), creatinine (P = 0.223), GFR (P = 0.347), systolic blood pressure (P = 0.615), and diastolic blood pressure (P = 0.135) were not statistically significant.

Patients with DN who are on active vitamin D had significantly lower rates of proteinuria.

Reference:  journals.lww.com/jfmpc/Fulltext/2022/12000/Anti_proteinuria_effect_of_active_vitamin_D_in.28.aspx